MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

By H. Hirai, H. Sootome, Y. Nakatsuru, Katsuyoshi Miyama, Shunsuke Taguchi, K. Tsujioka, Y. Ueno, H. Hatch, P. Majumder, B. Pan and 1 more. Molecular Cancer Therapeutics, 2010

956 citations recorded by the source corpus.

Subfields: Molecular Biology, Organic Chemistry, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/49554f2d479f4f59b81e99ee0d3203fbeb8e1f70

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. P. Gentry
2. Thomas P Mathews
3. Cody J. Wenthur
4. Craig Lindsley

Citations in the corpus

• Drugs for allosteric sites on receptors. (2014, background): “The allosteric Akt kinase inhibitors represent a novel mechanism for kinase inhibition and a successful clinical development program that is currently in Phase II clinical trials (34).”
• Targeting PI3K/Akt signal transduction for cancer therapy (2021, background): “In addition, MK2206 inhibits the phosphorylation of Akt mediated by carboplatin and gemcitabine, thereby enhancing the therapeutic effect of the drug by inhibiting tumor survival laterally.(210) MK-2206 also enhances erlotinib activity in erlotinib-sensitive patients and erlotinib-resistant NSCLC ce”